IP Library › Granted Patent US 12,678,443
Granted Patent B2
US 12,678,443 · App. 18/655,985 · Granted Jul 14, 2026

Medicament for preventing and/or treating dry eye

Inventors: Kenji Oki (Minoh, JP); Takashi Nagano (Osaka, JP); Nagayoshi Asano (Ikoma, JP); Koushi Fujisawa (Ikoma, JP)
Assignees: SANTEN PHARMACEUTICAL CO., LTD.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH
A61K31/536A61K31/538A61P27/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,678,443
App. No.
18/655,985
Filed
May 6, 2024
Granted
Jul 14, 2026
Kind
B2
Art Unit
1624
USPC
514/230.5
Abstract

A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. A method of preventing and/or treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol or a salt thereof to the subject is also provided.

Claims (10)

1 . A method of stabilizing tear film in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol hydrochloride to the subject.

2 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.1% (w/v) or less.

3 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.01% (w/v) or less.

4 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.1% (w/v).

5 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.01% (w/v).

6 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.005% (w/v).

7 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.001% (w/v).

8 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.0001 to 0.001% (w/v).

9 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in the form of an eye drop.

10 . The method according to claim 1 , wherein administering the olodaterol hydrochloride does not substantially increase and/or reduce intraocular pressure.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2024
From: OKI, KENJI; NAGANO, TAKASHI; ASANO, NAGAYOSHI; FUJISAWA, KOUSHI
To: SANTEN PHARMACEUTICAL CO., LTD.
Reel/Frame 067561/0050 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2024
From: SANTEN PHARMACEUTICAL CO., LTD.
To: SANTEN PHARMACEUTICAL CO., LTD.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 067561/0067 →
Priority Claims (1)
JP 2021-150112 · Sep 15, 2021 · national
Continuity (3)
Continuation 17722947 · Apr 18, 2022
Continuation 17513593 · Oct 28, 2021
Related Publication 20240293417A1 · Sep 5, 2024
References Cited (28)
US 5981607A · Ding et al. · 1999 [cited by applicant]
US 11331322B1 · Oki et al. · 2022 [cited by applicant]
US 12005063B2 · Oki et al. · 2024 [cited by applicant]
US 20030008805A1 · Honma et al. · 2003 [cited by applicant]
US 20220098164A1 · Collingwood et al. · 2022 [cited by applicant]
US 20230087826A1 · Oki et al. · 2023 [cited by applicant]
US 20240374607A1 · Oki et al. · 2024 [cited by applicant]
CN 110062625A · 2019 [cited by applicant]
WO WO2001041806A1 · 2001 [cited by applicant]
WO WO2011068786A2 · 2011 [cited by applicant]
WO WO2017043612A1 · 2017 [cited by applicant]
WO WO2018108669A1 · 2018 [cited by applicant]
WO WO2019020634A2 · 2019 [cited by applicant]
WO WO2019230230A1 · 2019 [cited by applicant]
WO 2020249956A1 · 2020 [cited by applicant]
WO WO2020251926A1 · 2020 [cited by applicant]
WO WO2023042851A1 · 2023 [cited by applicant]
U.S. Appl. No. 18/691,241, filed Mar. 12, 2024, Oki et al. [cited by applicant]
Notice of Allowance mailed Jan. 20, 2022 in U.S. Appl. No. 17/513,593 (7 pages). [cited by applicant]
International Search Report and Written Opinion dated Nov. 29, 2022 for PCT/JP2022/034383 (8 pages). [cited by applicant]
Office Action issued Jul. 27, 2023 in Chinese Patent Application No. 202280006228.4 (19 pages, including English translation) (note: Chinese Patent Application No. 202280006228.4 is a foreign counterpart of U.S. Appl. N… [cited by applicant]
Shen, J. et al., 2013, “Olodaterol hydrochloride, a long acting bronchodilator,” Shanghai Medical & Pharmaceutical Journal, 34(15):19-21 (9 pages including English translation). [cited by applicant]
Notice of Allowance mailed Feb. 7, 2024 in U.S. Appl. No. 17/722,947 (5 pages). [cited by applicant]
Office Action dated Oct. 10, 2023 in U.S. Appl. No. 17/722,947 (5 pages). [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/JP2022/034383, International Bureau of WIPO, Switzerland, issued Mar. 5, 2024 (4 pages). [cited by applicant]
Extended European Search Report mailed Jul. 22, 2025 for EP 22869998.9 (8 pages). [cited by applicant]
Masakazu Ichinose et al., 2015, “Efficacy and safety of the long-acting ß2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease,” International Journal of COPD, 10:1673-1683. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 18/691,241 dated Mar. 13, 2026. [cited by applicant]